Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 408

1.

A circRNA signature predicts postoperative recurrence in stage II/III colon cancer.

Ju HQ, Zhao Q, Wang F, Lan P, Wang Z, Zuo ZX, Wu QN, Fan XJ, Mo HY, Chen L, Li T, Ren C, Wan XB, Chen G, Li YH, Jia WH, Xu RH.

EMBO Mol Med. 2019 Sep 2:e10168. doi: 10.15252/emmm.201810168. [Epub ahead of print]

2.

Normative Profile of Health-Related Quality of Life for Hong Kong General Population Using Preference-Based Instrument EQ-5D-5L.

Wong EL, Cheung AW, Wong AY, Xu RH, Ramos-Goñi JM, Rivero-Arias O.

Value Health. 2019 Aug;22(8):916-924. doi: 10.1016/j.jval.2019.02.014. Epub 2019 Jul 27.

PMID:
31426933
3.

Evaluation of POLE and POLD1 Mutations as Biomarkers for Immunotherapy Outcomes Across Multiple Cancer Types.

Wang F, Zhao Q, Wang YN, Jin Y, He MM, Liu ZX, Xu RH.

JAMA Oncol. 2019 Aug 15. doi: 10.1001/jamaoncol.2019.2963. [Epub ahead of print] No abstract available.

4.

Designing gene panels for tumor mutational burden estimation: the need to shift from 'correlation' to 'accuracy'.

Wu HX, Wang ZX, Zhao Q, Wang F, Xu RH.

J Immunother Cancer. 2019 Aug 6;7(1):206. doi: 10.1186/s40425-019-0681-2.

5.

Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis.

Wang ZX, Wu HX, He MM, Wang YN, Luo HY, Ding PR, Xie D, Chen G, Li YH, Wang F, Xu RH.

J Natl Compr Canc Netw. 2019 Jul 1;17(7):805-811. doi: 10.6004/jnccn.2018.7279.

PMID:
31319395
6.

Correction: ME1 Regulates NADPH Homeostasis to Promote Gastric Cancer Growth and Metastasis.

Lu YX, Ju HQ, Liu ZX, Chen DL, Wang Y, Zhao Q, Wu QN, Zeng ZL, Qiu HB, Hu PS, Wang ZQ, Zhang DS, Wang F, Xu RH.

Cancer Res. 2019 Jul 15;79(14):3789. doi: 10.1158/0008-5472.CAN-19-1611. No abstract available.

PMID:
31308137
7.

Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD1 antibody in phase Ib/II clinical trial NCT02915432.

Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, Yuan XL, Chen Y, Yang SJ, Shi JH, Hu XC, Lin XY, Zhang QY, Feng JF, Ba Y, Liu YP, Li W, Shu YQ, Jiang Y, Li Q, Wang JW, Wu H, Feng H, Yao S, Xu RH.

Ann Oncol. 2019 Jun 24. pii: mdz197. doi: 10.1093/annonc/mdz197. [Epub ahead of print]

PMID:
31236579
8.

METTL3 facilitates tumor progression via an m6A-IGF2BP2-dependent mechanism in colorectal carcinoma.

Li T, Hu PS, Zuo Z, Lin JF, Li X, Wu QN, Chen ZH, Zeng ZL, Wang F, Zheng J, Chen D, Li B, Kang TB, Xie D, Lin D, Ju HQ, Xu RH.

Mol Cancer. 2019 Jun 24;18(1):112. doi: 10.1186/s12943-019-1038-7.

9.

Genome sequencing analysis identifies Epstein-Barr virus subtypes associated with high risk of nasopharyngeal carcinoma.

Xu M, Yao Y, Chen H, Zhang S, Cao SM, Zhang Z, Luo B, Liu Z, Li Z, Xiang T, He G, Feng QS, Chen LZ, Guo X, Jia WH, Chen MY, Zhang X, Xie SH, Peng R, Chang ET, Pedergnana V, Feng L, Bei JX, Xu RH, Zeng MS, Ye W, Adami HO, Lin X, Zhai W, Zeng YX, Liu J.

Nat Genet. 2019 Jul;51(7):1131-1136. doi: 10.1038/s41588-019-0436-5. Epub 2019 Jun 17.

PMID:
31209392
10.

Prospective observation: Clinical utility of plasma Epstein-Barr virus DNA load in EBV-associated gastric carcinoma patients.

Qiu MZ, He CY, Lu SX, Guan WL, Wang F, Wang XJ, Jin Y, Wang FH, Li YH, Shao JY, Zhou ZW, Yun JP, Xu RH.

Int J Cancer. 2019 Jun 4. doi: 10.1002/ijc.32490. [Epub ahead of print]

PMID:
31162842
11.

Suppression of fumarate hydratase activity increases the efficacy of cisplatin-mediated chemotherapy in gastric cancer.

Yu HE, Wang F, Yu F, Zeng ZL, Wang Y, Lu YX, Jin Y, Wang DS, Qiu MZ, Pu HY, Kang TB, Xie D, Ju HQ, Xu RH, Luo HY.

Cell Death Dis. 2019 May 28;10(6):413. doi: 10.1038/s41419-019-1652-8.

12.

[Clinical research progress of cell immunity in gastric cancer].

Xu RH, Wu J, Chen M, Zou X, Liu SL.

Zhonghua Zhong Liu Za Zhi. 2019 May 23;41(5):321-325. doi: 10.3760/cma.j.issn.0253-3766.2019.05.001. Chinese.

PMID:
31137163
13.

Probiotic and hepatoprotective activity of lactobacillus isolated from Mongolian camel milk products.

Xu RH, Xiu L, Zhang YL, Du RP, Wang X.

Benef Microbes. 2019 May 24:1-12. doi: 10.3920/BM2018.0131. [Epub ahead of print]

PMID:
31122041
14.

A real-world evidence of efficacy of palliative gastrectomy plus chemotherapy in metastatic gastric cancer patients.

Yang LP, Wang ZX, He MM, Wu HX, Yuan SQ, Wang W, Jin Y, Ren C, Wang ZQ, Wang FH, Li YH, Wang F, Xu RH.

Cancer Manag Res. 2019 May 2;11:3993-4003. doi: 10.2147/CMAR.S197052. eCollection 2019.

15.

Mutation spectrum of germline cancer susceptibility genes among unselected Chinese colorectal cancer patients.

Gong R, He Y, Liu XY, Wang HY, Sun LY, Yang XH, Li B, Cao XK, Ye ZL, Kong LH, Zhang DD, Li YH, Xu RH, Shao JY.

Cancer Manag Res. 2019 Apr 29;11:3721-3739. doi: 10.2147/CMAR.S193985. eCollection 2019.

16.

Phase I study of high-dose ascorbic acid with mFOLFOX6 or FOLFIRI in patients with metastatic colorectal cancer or gastric cancer.

Wang F, He MM, Wang ZX, Li S, Jin Y, Ren C, Shi SM, Bi BT, Chen SZ, Lv ZD, Hu JJ, Wang ZQ, Wang FH, Wang DS, Li YH, Xu RH.

BMC Cancer. 2019 May 16;19(1):460. doi: 10.1186/s12885-019-5696-z.

17.

Correction: Targeting CDH17 Suppresses Tumor Progression in Gastric Cancer by Downregulating Wnt/β-Catenin Signaling.

Qiu HB, Zhang LY, Ren C, Zeng ZL, Wu WJ, Luo HY, Zhou ZW, Xu RH.

PLoS One. 2019 May 16;14(5):e0217124. doi: 10.1371/journal.pone.0217124. eCollection 2019.

18.

Eukaryotic initiation factor 4A2 promotes experimental metastasis and oxaliplatin resistance in colorectal cancer.

Chen ZH, Qi JJ, Wu QN, Lu JH, Liu ZX, Wang Y, Hu PS, Li T, Lin JF, Wu XY, Miao L, Zeng ZL, Xie D, Ju HQ, Xu RH, Wang F.

J Exp Clin Cancer Res. 2019 May 14;38(1):196. doi: 10.1186/s13046-019-1178-z.

19.

The efficacy and safety of modified FOLFIRINOX as first-line chemotherapy for Chinese patients with metastatic pancreatic cancer.

Wang ZQ, Zhang F, Deng T, Zhang L, Feng F, Wang FH, Wang W, Wang DS, Luo HY, Xu RH, Ba Y, Li YH.

Cancer Commun (Lond). 2019 May 8;39(1):26. doi: 10.1186/s40880-019-0367-7.

20.

Correlation of Milestone Restricted Mean Survival Time Ratio With Overall Survival Hazard Ratio in Randomized Clinical Trials of Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.

Wang ZX, Wu HX, Xie L, Wang YN, Yang LP, He MM, Luo HY, Ding PR, Xie D, Chen G, Li YH, Wang F, Xu RH.

JAMA Netw Open. 2019 May 3;2(5):e193433. doi: 10.1001/jamanetworkopen.2019.3433.

Supplemental Content

Support Center